Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Randomised Maternal and Infant (From 4 to 24 Months of Age) Safety and Immunogenicity Trial of MVA-BN® Vaccine in the Democratic Republic of the Congo

NCT06844500 is registered in ClinicalTrials.gov with Jean-Pierre Van geertruyden as lead sponsor.

NCT NCT06844500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06844500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Randomised Maternal and Infant (From 4 to 24 Months of Age) Safety and Immunogenicity Trial of MVA-BN® Vaccine in the Democratic Republic of the Congo
Lead sponsor
Jean-Pierre Van geertruyden
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 23, 2025
Completion date
May 31, 2027
Enrollment
359 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunogenicity, maternal transmission, mpox, neonate, postpartum, pregnancy, safety, vaccination